WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006125596) ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/125596    International Application No.:    PCT/EP2006/004851
Publication Date: 30.11.2006 International Filing Date: 22.05.2006
IPC:
C07D 295/16 (2006.01), A61K 31/40 (2006.01), A61K 31/445 (2006.01), A61P 29/00 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH) (For All Designated States Except US).
AXFORD, Jake [GB/GB]; (GB) (For US Only).
BAETTIG, Urs [CH/GB]; (GB) (For US Only).
COX, Brian [GB/GB]; (GB) (For US Only).
BALA, Kamlesh, Jagdis [GB/GB]; (GB) (For US Only).
LEBLANC, Catherine [GB/GB]; (GB) (For US Only).
SANDHAM, David, Andrew [GB/GB]; (GB) (For US Only)
Inventors: AXFORD, Jake; (GB).
BAETTIG, Urs; (GB).
COX, Brian; (GB).
BALA, Kamlesh, Jagdis; (GB).
LEBLANC, Catherine; (GB).
SANDHAM, David, Andrew; (GB)
Agent: ROTH, Peter, R.; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH)
Priority Data:
0510584.6 24.05.2005 GB
Title (EN) ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS
(FR) COMPOSES ORGANIQUES DESTINES AU TRAITEMENT D'ETATS INFLAMMATOIRES OU ALLERGIQUES
Abstract: front page image
(EN)Compounds of formula (I) in free or pharmaceutically acceptable salt form, where R1, R2, R3, R4, R5, R6, R7, m, n, w, X, and Y have the meanings as indicated in the specification, are useful for treating conditions mediated by the CRTh2 receptor, especially inflammatory or obstructive airways diseases.
(FR)L'invention concerne des composés de formule (I) sous forme de sel libre ou acceptable sur le plan pharmaceutique, dans laquelle R1, R2, R3, R4, R5, R6, R7, m, n, w, X et Y ont les significations présentées dans la description, ces composés étant utiles dans le traitement d'états induits par le récepteur CRTh2, notamment des maladies inflammatoires ou obstructives.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)